Eli Lilly (LLY) Stock Analysis 2026: GLP-1 Phenomen, 42% Revenue Growth, PEG 1.0 — Q1 Earnings April 30

Eli Lilly (LLY) Stock Analysis 2026: GLP-1 Phenomen, 42% Revenue Growth, PEG 1.0 — Q1 Earnings April 30

Eli Lilly ($LLY) has become the defining growth story in large-cap pharmaceuticals — and arguably in all of US equities — through its tirzepatide franchise (Mounjaro for diabetes, Zepbound for obesity). The $829 billion market capitalization reflects a market that believes it is watching the early innings of the largest drug category in history unfold. The company reports Q1 2026 earnings on April 30, 2026.

Revenue grew 42.6% year-over-year in the most recent quarter. Earnings per share grew 51.4%. Gross margin is 83.1%. Operating margin is 44.9%. These are extraordinary numbers for a company of this size, and they are accelerating, not decelerating. At the same time, the stock trades 18% below its 52-week high of $1,132 — an entry point that has attracted significant institutional attention.

Fundamental Snapshot

Valuation Analysis: Conservative Methods Fail Here, PEG Tells the Real Story

Our multi-method model assigns LLY a Margin of Safety of -94.8%, classifying the stock as significantly above conservative intrinsic value estimates. This is expected — and here is why the model's limitations are most visible with LLY.

Graham Number = v(22.5 — $22.99 EPS — $29.66 book value) — $123.87 — far below $928. Eli Lilly's book value ($29.66/share) is tiny relative to its earnings power, because the company's most valuable assets — Mounjaro/Zepbound IP, FDA approvals, manufacturing scale, clinical pipeline — do not appear on the balance sheet. Graham's formula was designed for industrial companies with tangible assets. It fails for IP-driven pharma.

Earnings Power Value (EPV): At 44.9% operating margin on $65.2B revenue, operating income is approximately $29.3B. Capitalized at 8% ? EPV roughly $327/share. Still well below $928, but getting closer to reality. The gap reflects the market's pricing of future growth that EPV (which assumes no growth) explicitly excludes.

The PEG ratio is the most honest lens: At forward PE 27.32x with EPS growing 51.4% annually, PEG = 1.002. A PEG below 1.0 is rare for quality companies. At 1.0, the math says you are paying exactly one dollar of forward earnings multiple for each percentage point of expected growth. For a pharma company growing at 50%+ with 83% gross margins, this is not a stretched valuation — it is a reasonable price for the growth on offer.

Analyst consensus: 34 analysts cover LLY. The consensus target of $1,209.86 implies +30.4% upside from $928. This is a high-conviction bullish consensus driven by tirzepatide market share projections, label expansions, and Alzheimer's optionality.

The honest picture: Eli Lilly is not a value play. Conservative methods (Graham, EPV) show massive negative MoS because book value is irrelevant and EPV excludes growth. The forward earnings multiple (27.32x) for 50%+ growth is the correct frame. The question is not "is LLY cheap?" — it is "can 50%+ growth persist long enough to justify today's multiple?"

Tirzepatide: The GLP-1 Revolution

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the only drug of its class approved for both type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). In clinical trials, tirzepatide produced average weight loss of 20-22.5% from baseline — approximately double what earlier GLP-1 drugs achieved.

The obesity market is massive and underpenetrated: An estimated 40% of US adults have obesity, and fewer than 5% are currently on any pharmacotherapy. Zepbound's approval opened a multi-hundred-billion dollar total addressable market. LLY and Novo Nordisk (semaglutide: Ozempic/Wegovy) are the two dominant players at the moment.

Revenue trajectory: Mounjaro and Zepbound together generated over $10B in their first full year of combined availability. The run rate is accelerating quarterly. Manufacturing constraints, not demand, have been the limiting factor.

Label expansion pipeline: LLY is pursuing additional indications for tirzepatide: NASH/MASH (non-alcoholic steatohepatitis), sleep apnea, heart failure, and kidney disease. Each approval would expand the addressable market significantly. The FDA approved tirzepatide for sleep apnea in 2025, adding millions of eligible patients.

Manufacturing ramp: Lilly has committed billions of dollars to new manufacturing facilities in Indiana, North Carolina, and internationally. Every new vial-filling line increases the revenue ceiling. Supply remains a constraint heading into 2026 — any update on manufacturing scale-up in Q1 earnings is a key catalyst.

Beyond GLP-1: Pipeline Depth

Eli Lilly is not a one-drug company, even though tirzepatide dominates the near-term narrative.

Alzheimer's disease: LLY's donanemab received FDA approval in 2024 for early symptomatic Alzheimer's (the anti-amyloid antibody class). While the commercial ramp is slower than hoped (payer coverage, patient eligibility screening), Alzheimer's is a multi-decade opportunity. The market for disease-modifying Alzheimer's therapy is estimated at $15-25B annually at peak.

Oncology: Verzenio (abemaciclib) for early breast cancer continues to grow. Several LLY oncology pipeline assets are in Phase 2/3.

Orforglipron: An oral GLP-1 agonist in Phase 3 trials. If approved, it would eliminate the injection barrier — dramatically expanding the addressable population. An oral weight loss pill with tirzepatide-like efficacy would be a blockbuster beyond current GLP-1 revenue.

Cardiovascular: SURPASS-CVOT data confirms tirzepatide's cardiovascular benefit — positioning it for primary and secondary CV prevention, a massive indication.

Q1 2026 Earnings Preview (April 30)

Key data points to watch when Lilly reports:

Mounjaro revenue: Quarter-over-quarter and year-over-year growth. Any guidance raise signals tirzepatide demand is outpacing supply constraints.

Zepbound ramp: The obesity (Zepbound) label had fewer pre-existing patients versus the diabetes (Mounjaro) label — its revenue trajectory tells the growth story.

Supply commentary: Have new manufacturing facilities ramped? Is LLY still supply-constrained, or is demand now the binding constraint? This determines the medium-term revenue ceiling.

Donanemab sales: Early commercial data on the Alzheimer's drug — payer coverage updates and patient uptake numbers.

Full-year 2026 guidance: Any raise to full-year revenue and EPS guidance is the most important catalyst. LLY's prior guidance has been consistently raised throughout 2024-2025.

Margin trajectory: As tirzepatide manufacturing scales, unit economics improve. Operating margin improvement commentary would be a positive signal.

Risks

Competition from Novo Nordisk: Ozempic (semaglutide, weekly injection) and Wegovy (semaglutide for obesity) are LLY's primary competitors. Novo Nordisk also has CagriSema (next-gen combination) in development. A competitive data readout favoring Novo's new drugs would pressure LLY's market share assumptions.

Manufacturing constraints becoming a demand problem: If LLY's manufacturing scale catches up but payer coverage restrictions limit patient access, the demand side could disappoint.

IRA drug pricing: The Inflation Reduction Act created Medicare price negotiation for high-revenue drugs. Mounjaro could face pricing pressure from CMS negotiation. This is a long-term margin headwind.

Patent protection: Tirzepatide has patent protection until at least 2036 in the US. However, biosimilar entry in international markets and potential compounding pharmacy competition (which regulators have been addressing) remain watch items.

Valuation multiple at risk: At 27x forward PE and PEG 1.0, any slowdown in revenue or earnings growth would compress the multiple. If growth decelerates from 42% to 15%, the fair multiple drops substantially.

Donanemab disappointment: If Alzheimer's drug uptake remains slow due to payer coverage or patient eligibility challenges, the pipeline optionality priced into LLY compresses.

What Our Valuation Tools Show

• P/E Ratio Calculator: At 40.32x trailing PE but 27.32x forward PE, the forward multiple is the operative number — and represents substantial earnings growth embedded in 2026 guidance.
• EV/EBITDA Calculator: 27.24x EV/EBITDA on 83% gross margin and 44.9% operating margin is a premium consistent with best-in-class pharma compounders.
• PEG Ratio Calculator: PEG of 1.002 is the most important single metric for LLY — at 1.0 PEG, the forward PE exactly matches the expected growth rate. Historically, quality compounders at PEG 1.0 have proven rewarding.

Our screener gives LLY a SAVE score of 52.4/100 and risk score 31.6/100. The SAVE score reflects the negative MoS from conservative methods (Graham, EPV) that penalize LLY's low book value. The risk score of 31.6 (low-medium) reflects low beta (0.504), consistent earnings growth, and strong balance sheet — not the elevated multiple.

Bottom Line

Eli Lilly is the defining pharma story of this decade. Tirzepatide is generating $65B in annualized revenue with 42%+ quarterly growth and 83% gross margins. The GLP-1 obesity market is the largest drug category in history by addressable population. At PEG 1.002, the market is not irrationally pricing this franchise — it is pricing in continued execution of the tirzepatide ramp plus pipeline optionality (oral GLP-1, Alzheimer's, cardiovascular indications).

The model's MoS of -94.8% reflects the limits of conservative valuation on a compound that is fundamentally changing pharmacotherapy for chronic disease. The analyst consensus of $1,210 (+30%) reflects the buy-side's confidence that tirzepatide demand continues to outgrow supply well into 2027-2028.

April 30 Q1 2026 earnings will provide the most current data on the tirzepatide ramp. Watch tirzepatide combined revenue, manufacturing commentary, and any guidance raise.

Next earnings: April 30, 2026 (Q1 2026)

This analysis uses Equity Rank's multi-method valuation model combining Graham Number, EPV, DCF, and comparable multiples. SAVE score and MoS reflect model outputs, not investment recommendations. All data as of April 19, 2026. Not investment advice. See full disclaimer below.

Equity Rank is an independent financial research and analysis platform. We are not registered investment advisers. Nothing on this platform constitutes a recommendation to purchase, hold, or divest any security. All content is for informational and educational purposes only. Investors should conduct their own due diligence and consult a licensed financial professional before making investment decisions.